# Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)

> **NCT01039103** · PHASE2 · TERMINATED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 15 (actual)

## Conditions studied

- Acute Exacerbation of Remitting Relapsing Multiple Sclerosis
- Clinically Isolated Syndrome

## Interventions

- **DRUG:** PEG-liposomal prednisolone sodium phosphate
- **DRUG:** Methylprednisolone

## Key facts

- **NCT ID:** NCT01039103
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-12
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2016-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01039103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01039103, "Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01039103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*